Welcome to Dendright

Dendright Pty Limited is a clinical stage biopharmaceutical company commercializing an immune tolerizing immunotherapy for rheumatoid arthritis.

The Company’ s technology targets dendritic cells that present and orchestrate the body’s immune responses to foreign and self-antigens. Dendright’s tolerizing immunotherapy acts to down regulate the immune system rather than to activate it, such that immune responses to given self-antigens are ‘turned off’. By targeting the cause of autoimmune disease rather than treating the symptoms, Dendright offers the potential for long-lasting treatment by working with the body’s own immune system to fight disease.  

In 2013, Dendright entered into a R&D collaboration and option-to-license agreement with US-based Janssen Biotech, Inc. for the exclusive worldwide right to develop and commercialize Dendright’s rheumatoid arthritis immunotherapy.